NOVO-B.CO Novo Nordisk A/S
Company Analysis
Latest News
Novo Nordisk targets Wegovy insurance growth, ahead of July Medicare pilot
Novo Nordisk U.S. head Jamey Millar aims to rebalance Wegovy sales between insurance coverage and direct-to-consumer purchases. Self-pay consumers currently...
Novo Nordisk Rallies 5%, Foundation Launches $69 Million Obesity Research Hub
The Novo Nordisk Foundation launched the CardioMetabolic Bridge on Friday to commercialize academic research in obesity and type 2 diabetes. This pan-European...
🟢 Novo Nordisk A/S extends move to 5.1% up
NOVO-B.CO is trading at $294.30, up 5.1% versus the comparison close of $280.10 during regular trading. This is a price-movement alert; no separate...
🟢 Novo Nordisk A/S is trading 4.4% up today on positive obesity drug updates and UK Wegovy approval
Novo Nordisk A/S is trading 4.4% up now at $292.55, extending a rebound after earlier mid-June weakness as investors react to positive clinical and regulatory...
Novo Nordisk Rejects $25 Million Ransom, Hackers Leak 1.3TB Data
Cyber-extortion group FulcrumSec claimed responsibility for a major data breach at Novo Nordisk involving 1.3 terabytes of stolen information. The group began...
🟢 Novo Nordisk A/S is trading 2.2% up today on plans for oral Wegovy approval in China
Novo Nordisk A/S is trading 2.2% up today at $292.45 after the company announced plans to seek regulatory approval for an oral version of its Wegovy...
Novo Nordisk seeks China approval for Wegovy pill, countering generic threats
Novo Nordisk will seek regulatory approval for an oral version of its weight-loss drug Wegovy in China. CEO Mike Doustdar announced the plan on Tuesday, with...
Novo Nordisk Wins UK Approval for Wegovy Pill, First Weight-Loss Tablet
Novo Nordisk received approval from the U.K. Medicines and Healthcare products Regulatory Agency for its daily Wegovy weight-loss pill. This marks the first...
Novo Nordisk sues South African pharmacy over unauthorized Wegovy and Ozempic
Novo Nordisk filed a lawsuit in a South African high court against local compounding pharmacy iDexis. The pharmaceutical giant seeks an injunction to halt the...
🟢 Novo Nordisk A/S is trading 3.65% up
NOVO-B.CO is trading at $281.30, up 3.65%.
Novo Nordisk Wegovy pill hits 3M scripts, drawing 80% new users
Novo Nordisk’s Wegovy weight-loss pill surpassed 3 million U.S. prescriptions within five months of its January 5, 2026, launch. This milestone represents one...
Novo Nordisk's CagriSema shows significant blood sugar and weight reduction in late-stage trials
Novo Nordisk presented positive results from three Phase 3 trials of its investigational drug, CagriSema, at the American Diabetes Association's (ADA) 2026...